

Queensland: An investment-ready biomedical destination

Invest in the future with Queensland, where world-class biomedical research and talent, advanced manufacturing, globally- accepted clinical trial data, Asia-Pacific connections and an enviable lifestyle create the ideal environment for success.



Image supplied by QIMR Berghofer

**DELIVERING
FOR QUEENSLAND**



**Queensland
Government**

Queensland's biomedical sector at a glance



230+ biomedical companies



\$533 million in biomedical exports



27,300+ people employed across industry and research



Gateway to Asia-Pacific markets



\$4.15 billion contribution to Queensland's economy



Diverse population across 1.7 million square kilometres



Tropical and subtropical climate zones

Queensland: from discovery to market

Research and talent

Queensland connects internationally-recognised universities, research institutes, teaching hospitals and health precincts to support discovery, clinical development and industry collaboration.

- Seven of Queensland's eight universities rank in the world's top 500.
- Queensland universities spent \$1.83 billion on translational research in 2024.
- More than 350,000 Queenslanders worked in STEM jobs in 2024.
- The Queensland technology sector contributes about \$15 billion to the state economy.
- Specialised research strengths include immunology and vaccine development, tropical medicine and infectious diseases, precision imaging, and biomaterials.
- Five health and knowledge precincts connect researchers, clinicians and industry to accelerate the pathway from discovery to market.

Biomedical is one of three industries the Queensland Government has prioritised for growth, backed by strategic investment and long-term industry development. Through the Sovereign Industry Development Fund (SIDF), the Government is investing \$180.6 million across the biomedical, defence and biofuels sectors to strengthen sovereign capability, attract private investment and create highly skilled jobs across Queensland.



Image supplied by Queensland Health

Streamlined, globally-compliant clinical trials



Queensland's clinical trials network. A collaborative state-wide network of public and private trial capabilities supported by government and ICH-GCP standards.



R&D tax incentive
Up to 48.5% R&D tax refund for eligible entities.



Patient diversity
Access to regionally diverse populations across tropical and sub-tropical environments.



Patient recruitment
Patient identification in weeks, not months.



Fast regulatory pathway. Trial activation in weeks, not months.



Favorable exchange rate.
Exchange rate supports cost savings.



Globally accepted by major regulations. Clinical trial data generated in Australia is routinely accepted by key international regulatory authorities, including the U.S. FDA, European Medicines Agency (EMA), Japan's PMDA and the UK's MHRA.



Statewide digital integration through a single electronic medical record (ieMR) system connecting 89 facilities across more than 1,500 kilometres.

Spotlight

Collaboration across government, academia and industry has helped attract global biomedical companies to Queensland, including Sanofi and Stryker, demonstrating the strength of our *Team Queensland* approach.

Advanced contract biomanufacturing supporting novel therapies

Queensland supports the development of cutting-edge vaccines, personalised medicines and complementary medicines, with modalities including biologics, RNA-based and cell therapies.

	Pre-clinical	Phase 1 Clinical	Clinical	Commercial
 UQ	██████████	████████████████████		
 GRIFFITH UNIVERSITY	██████████	████████████████████		
 TRI	██████████	████████████████████		
 Southern RNA	██████████	████████████████████	████████████████████	
 Q-Gen Cell Therapeutics	██████████	████████████████████	████████████████████	
 Sacco system	██████████	████████████████████	████████████████████	████████████████████
 ENTRISTAR		████████████████████	████████████████████	████████████████████
 ThermoFisher SCIENTIFIC			████████████████████	████████████████████
 BiomeCentric				████████████████████
 bjp				████████████████████

UQ's Pre-clinical capability = BASE,NBF,TM1,NIF,ANFF, AOF; Phase 1 Clinical capability = BASE/NBF/TM1. Note: TM1 currently under construction.

GU's Pre-clinical and Phase 1 Clinical capability = IBG. Sacco Systems pilot facility in Queensland has been designed to feed into overseas commercial sites.

Clinical-scale manufacturing pending GMP certification.

* ENTRISTAR is designed to support clinical and commercial-scale cGMP manufacturing, subject to regulatory approval.

Investment-ready and open for business

Queensland combines industry capability with government support to help businesses establish, expand and grow.

01 Biomedical is a Queensland Government priority industry.

02 Focused on building sovereign manufacturing capability, securing critical supply chains and creating high-value jobs.

03 Coordinated support from initial engagement through project delivery and ongoing growth.

Whether you're looking to invest, expand, commercialise, manufacture or collaborate, Queensland offers the connections, capability and support to accelerate your next stage of growth.

Email: Biomedical@dsdip.qld.gov.au



Building sovereign manufacturing capability

Australian-founded radiopharmaceutical company AdvanCell is establishing Australia's first sovereign manufacturing capability for Thorium-228, a key upstream isotope used to produce Lead-212 for targeted alpha therapies in development for cancer treatment.

Supported by the Queensland Government's *Sovereign Industry Development Fund*, the project will enable AdvanCell to scale a secure radioisotope supply chain and advance innovative production methods.

Working with partners across Australia including The University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN), the Translational Research Institute (TRI), Princess Alexandra Hospital (PAH), the Royal Brisbane and Women's Hospital (RBWH) and the Gold Coast University, AdvanCell is using Queensland technical expertise and infrastructure to advance the development of innovative Lead-212 targeted alpha therapies.



Image supplied by AdvanCell

Global partnership, local impact

The Translational Science Hub (TSH), a partnership between the Queensland Government, Sanofi, The University of Queensland and Griffith University, is accelerating the development of next-generation vaccines and healthcare solutions while strengthening Queensland's biomedical ecosystem.

By connecting Queensland's world-class research capability with Sanofi's global vaccine R&D network, the partnership is attracting investment, expanding clinical trial activity and building specialist skills. Since its establishment in 2022, Queensland has become a key location for Sanofi's vaccine development programs, supporting clinical trials, research collaborations and new jobs across the state.

The partnership is also helping grow clinical research capability in regional Queensland, creating new opportunities for participation in trials and strengthening Australia's broader life sciences ecosystem.



Image supplied by Sanofi